Cargando…
Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression
The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosis of neovascular age-related macular degeneration (nAMD). As clinical experiences have accumulated, it has become mandatory to summarize data to give information that can be useful in everyday practic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781865/ https://www.ncbi.nlm.nih.gov/pubmed/35054021 http://dx.doi.org/10.3390/jcm11020325 |
_version_ | 1784638182767198208 |
---|---|
author | Veritti, Daniele Sarao, Valentina Soppelsa, Valentina Danese, Carla Chhablani, Jay Lanzetta, Paolo |
author_facet | Veritti, Daniele Sarao, Valentina Soppelsa, Valentina Danese, Carla Chhablani, Jay Lanzetta, Paolo |
author_sort | Veritti, Daniele |
collection | PubMed |
description | The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosis of neovascular age-related macular degeneration (nAMD). As clinical experiences have accumulated, it has become mandatory to summarize data to give information that can be useful in everyday practice. We conducted a systematic review to identify randomized controlled trials (RCTs) and observational studies that reported 12-month changes in best-corrected visual acuity (BCVA) in patients with nAMD on anti-VEGF monotherapy. Data were analyzed in a random-effects meta-analysis with BCVA change as the primary outcome. Meta-regression was conducted to evaluate the impact of multiple covariates. Four hundred and twelve heterogeneous study populations (109,666 eyes) were included. Anti-VEGFs induced an overall improvement of +5.37 ETDRS letters at 12 months. Meta-regression showed that mean BCVA change was statistically greater for RCTs (p = 0.0032) in comparison with observational studies. Populations following a proactive regimen had better outcomes than those following a reactive treatment regimen. Mean BCVA change was greater in younger populations, with lower baseline BCVA and treated with a higher number of injections (p < 0.001). Our results confirm that anti-VEGFs may produce a significant functional improvement at 12 months in patients with nAMD. |
format | Online Article Text |
id | pubmed-8781865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87818652022-01-22 Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression Veritti, Daniele Sarao, Valentina Soppelsa, Valentina Danese, Carla Chhablani, Jay Lanzetta, Paolo J Clin Med Review The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosis of neovascular age-related macular degeneration (nAMD). As clinical experiences have accumulated, it has become mandatory to summarize data to give information that can be useful in everyday practice. We conducted a systematic review to identify randomized controlled trials (RCTs) and observational studies that reported 12-month changes in best-corrected visual acuity (BCVA) in patients with nAMD on anti-VEGF monotherapy. Data were analyzed in a random-effects meta-analysis with BCVA change as the primary outcome. Meta-regression was conducted to evaluate the impact of multiple covariates. Four hundred and twelve heterogeneous study populations (109,666 eyes) were included. Anti-VEGFs induced an overall improvement of +5.37 ETDRS letters at 12 months. Meta-regression showed that mean BCVA change was statistically greater for RCTs (p = 0.0032) in comparison with observational studies. Populations following a proactive regimen had better outcomes than those following a reactive treatment regimen. Mean BCVA change was greater in younger populations, with lower baseline BCVA and treated with a higher number of injections (p < 0.001). Our results confirm that anti-VEGFs may produce a significant functional improvement at 12 months in patients with nAMD. MDPI 2022-01-10 /pmc/articles/PMC8781865/ /pubmed/35054021 http://dx.doi.org/10.3390/jcm11020325 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Veritti, Daniele Sarao, Valentina Soppelsa, Valentina Danese, Carla Chhablani, Jay Lanzetta, Paolo Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title | Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title_full | Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title_fullStr | Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title_full_unstemmed | Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title_short | Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression |
title_sort | managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781865/ https://www.ncbi.nlm.nih.gov/pubmed/35054021 http://dx.doi.org/10.3390/jcm11020325 |
work_keys_str_mv | AT verittidaniele managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression AT saraovalentina managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression AT soppelsavalentina managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression AT danesecarla managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression AT chhablanijay managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression AT lanzettapaolo managingneovascularagerelatedmaculardegenerationinclinicalpracticesystematicreviewmetaanalysisandmetaregression |